Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

GKOS

G

Glaukos Corporation (GKOS)

NYQ – Цена в реальном времени. Валюта: USD

103.18

-4.57 (-4.24%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

103.18

0.00 (0.00%)

После закрытия: Mar 27, 2026, 6:17 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.

Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?

Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook

Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook

GKOS posts 36% Q4 revenue jump, raises 2026 sales outlook to $600-$620M as iDose TR and Epioxa fuel growth despite wider loss.

These Analysts Boost Their Forecasts On Glaukos Following Q4 Results

These Analysts Boost Their Forecasts On Glaukos Following Q4 Results

Glaukos Corp (NYSE: GKOS) reported mixed results for the fourth quarter on Tuesday.

Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say

Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Видео

No Data

There is no data to display

Пресс-релизы

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis.

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos' 2025 NDA labeling supplement application, and re.

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $14.